

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Name of Product: Invesco Global Health Care Innovation Fund (the "Fund"), a sub-fund of Invesco Funds (the "Umbrella Fund"), Class A annual distribution - USD, (the "Share Class")

PRIP Manufacturer: Invesco Management S.A. ("IMSA"), part of the Invesco Group

ISIN: LU1775982595

<http://www.invescomanagementcompany.lu> or call +353 1 439 8100 for more information.

IMSA and the Fund are regulated by the Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg. The CSSF is responsible for supervising IMSA in relation to this Key Information Document ("KID").

This KID is accurate as at 7 May 2025.

What is this product?

Type

The Umbrella Fund is established under the laws of Luxembourg and harmonised under the EU Council Directive 2009/65/EC relating to Undertakings for Collective Investment in Transferable Securities (UCITS).

Term

The Fund does not have a maturity date and may only be terminated in accordance with the terms set out in the Prospectus.

Objectives

- The objective of the Fund is to achieve long-term capital growth.
- The Fund will invest primarily in shares of innovative healthcare companies worldwide.
- For the purpose of the Fund, healthcare companies include (but are not limited to), pharmaceuticals, biotechnology, healthcare services and medical technology and supplies.
- The Fund seeks to invest in companies that have the potential to materially improve the quality of care, access to care or cost of care through their innovative approach to products and services, use of technology, processes and business models, or management.
- The Fund may use securities lending for efficient portfolio management purposes.
- The Fund may use derivatives (complex instruments) to manage the Fund more efficiently, with the aim of reducing risk, reducing costs and/or generating additional capital or income.
- The Fund is actively managed and is not constrained by its benchmark, MSCI World Health Care Index (Net Total Return), which is used for comparison purposes. However, the majority of the Fund's holdings are likely to be components of the benchmark. As an actively managed fund, this overlap will change continuously and this statement may be updated from time to time.
- The Fund has broad discretion over portfolio construction and therefore securities, weightings and risk characteristics will differ. As a result, it is expected that over time the risk return characteristics of the Fund may diverge materially to the benchmark.

- You can buy and sell shares in the Fund on any Dealing Day (as defined in the Prospectus).

- Any income from your investment will be paid annually.

Intended Retail Investor

The Fund is intended for investors aiming for long term capital growth, who may not have specific financial expertise but are able to make an informed investment decision based on this document and the Prospectus, and have a risk appetite consistent with the risk indicator displayed below and understand that there is no capital guarantee or protection (100% of capital is at risk).

Practical Information

Depository: The Bank of New York Mellon SA/NV, Luxembourg Branch (the "Depository").

- IMSA may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus.

- The Umbrella Fund is structured by having different sub-funds. The assets and liabilities of each sub-fund are segregated by Luxembourg Law. The assets of the Fund will not be available to meet the liabilities of another sub-fund within the Umbrella Fund.

- You are entitled to switch from this Fund to another fund on request. Please refer to the Prospectus for more information.

- This KID describes one share class. More share classes may be available for this Fund. You can find more information on the Invesco local websites. You can check the latest price for the Share Class on our website and on Reuters, Bloomberg and Morningstar.

- The Prospectus and the annual and semi-annual reports can be obtained free of charge from the Fund's Registrar and Transfer Agent, The Bank of New York SA/NV, Luxembourg Branch, BP 648, L- 2016 Luxembourg, by emailing queries@invesco.com or on our website: www.invesco.com. The Prospectus is available in English, French, Spanish and German and the reports in English. The Prospectus and the reports are prepared for the entire Umbrella Fund.

What are the risks and what could I get in return?

Risk Indicator



Lower Risk

1

2

3

4

5

6

7

Higher Risk

The risk indicator assumes that you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 4 out of 7, which is a medium risk class.

This rates the potential losses from future performance at a medium level, and poor market conditions could impact the capacity of the PRIIPs manufacturer to pay you.

Be aware of currency risk. In some circumstances, you may receive payments in a different currency from your local currency, so the final return you will get may depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

Other risks such as Derivatives risks may impact the Fund. Please refer to the Prospectus for more details.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

The unfavourable scenario occurred for an investment between August 2021 and February 2025.

The moderate scenario occurred for an investment between March 2018 and March 2023.

The favourable scenario occurred for an investment between December 2016 and December 2021.

Recommended holding period: 5 years

Example Investment: USD 10,000

Scenarios		If you exit after 1 year	If you exit after 5 years
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress	What you might get back after costs	3,110 USD	2,990 USD
	Average return each year	-68.87 %	-21.48 %
Unfavourable	What you might get back after costs	7,610 USD	8,970 USD
	Average return each year	-23.88 %	-2.15 %
Moderate	What you might get back after costs	10,170 USD	13,050 USD
	Average return each year	1.71 %	5.46 %
Favourable	What you might get back after costs	12,470 USD	17,400 USD
	Average return each year	24.67 %	11.72 %

What happens if IMSA is unable to pay out?

The assets of the Fund are segregated from those of IMSA. The Depositary is responsible for the safekeeping of the assets of the Fund. To that effect, if IMSA defaults, there will be no direct financial impact on the Fund. In addition, the Fund's assets shall be segregated from the Depositary's assets, which limits the risk for the Fund suffering some loss in case of default of the Depositary. As a shareholder in the Fund, there is no compensation or guarantee scheme in place.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year, you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- USD 10,000 is invested.

	If you exit after 1 year	If you exit after 5 years
Total costs	720 USD	2,265 USD
Annual cost impact (*)	7.2%	3.4% each year

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 8.9% before costs and 5.5% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you.

Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	5.00 % of the amount you pay when entering this investment. This is the most you will be charged.	Up to 500 USD
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	0 USD
Ongoing costs [taken each year]		
Management fees and other administrative or operating costs	1.93% of the value of your investment per year. This is an estimate based on actual costs over the last year, or on expected costs if newly launched.	193 USD
Transaction costs	0.27% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	27 USD
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	0 USD

If you switch funds, you will pay a maximum switching charge of 1% on your new fund.

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

We have selected 5 years as the Fund invests for the long term.

You can sell your shares in the Fund on any Dealing Day as defined in the Prospectus.

If you sell some or all of your investment before 5 years the Fund will be less likely to achieve its objectives, however, you will not incur any additional costs by doing so.

How can I complain?

If you wish to make a complaint about the Fund, IMSA or any person advising or selling the Fund, you should write to The Bank of New York SA/NV, Luxembourg Branch, BP 648, L2016 Luxembourg or Invesco Management S.A., at 37a Avenue J.F. Kennedy, L-1855, Luxembourg, or send an e-mail to queries@invesco.com.

For more information, please refer to the Investor Complaint Handling Information Notice at www.invescomanagementcompany.lu.

Other relevant information

Remuneration Policy: Information on the up-to-date remuneration policy of IMSA, including but not limited to, a description of how remuneration and benefits are calculated and the identity of persons responsible for awarding the remuneration and benefits, including the composition of the remuneration committee, is available at www.invescomanagementcompany.lu and a copy can be obtained, free of charge, from IMSA.

Tax: The Luxembourg tax regime may have an impact on your personal tax position and there may be tax implications in your country of residence and/or origin.

Further Information on the Fund is made available to shareholders on www.invescomanagementcompany.lu and through the Invesco local websites.

Performance scenarios: You can find previous performance scenarios of the product at <https://www.invesco.com/emea/en/priips.html>.

Past performance: You can find the past performance of the product and of the benchmark (where relevant) over the last 10 years at <https://www.invesco.com/emea/en/priips.html>.